Scotiabank sees ‘deep value’ in Sage Therapeutics stock despite study setback By…
On Wednesday, Scotiabank revised its outlook on Sage Therapeutics (NASDAQ:SAGE), lowering its price target to $17 from $19 previously while maintaining a sector outperform rating on the stock.
The decision comes after the company's recent…
